Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 308 |
| Active Pipeline (Recruiting Now) | 236 (131) |
| Completed vs Stopped Early | 44 / 28 (9.1%) |
| Median Closed Actual Enrollment | 24 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Memorial Sloan Kettering Cancer Center | New York, NY | 298 |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, NJ | 131 |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, NJ | 129 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05657873 | A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) | Phase II | RECRUITING |
| NCT07111507 | A Study of Tarlatamab for People With Prostate Cancer | Phase II | RECRUITING |
| NCT05188508 | Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Phase II | RECRUITING |
| NCT04165772 | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | Phase II | RECRUITING |
| NCT06594991 | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | Phase II | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Memorial Sloan Kettering Cancer Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.